Premium Content VIDEO ASCO

Post-surgery osimertinib delays disease recurrence in patients with localised non-small-cell lung cancer

'The improvement in disease-free survival seen in this study strongly supports the use of this targeted therapy in earlier stage disease, which has a significant risk of recurrence despite surgical treatment and chemotherapy,' said ASCO CMO and Executive Vice President Richard Schilsky.

Please sign in or register for FREE

No comments yet.